Ann: CE, FDA and CFDA Approval - Guangzhou Production Facility, page-532

Hi @assailed, I am not challenging yours/ anyone's knowledge or perspective but my take on this is a simple fact that MediBio is trying to do something ground breaking/ Invention which no one does in past (or atleast company's are still exploring Tech in Mental Health) but G Med is trying to put the ages old medical tests into a mobile device aka Discovery, to make it cost effective and convenient to end user.

If you search around, almost all of the tests promised through the Prizma (even for future generations Prizma's) are already available on different mobile devices minus clearances from medical authorities e.g FDA, CFDA, CA etc (few devices are available with clearances from 1 or 2 authorities but not all). Same is the case with Patch, it is 'Holter monitor' + few more features like location, position etc which is available in many other wearable.

So to me, what GMV is doing it consolidating all the tests in 1 device and making the results more accurate to get approvals from different medical authorities.

Based on this my understanding is, GMV has much lower risk than MEB.